Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH
Status:
Not yet recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
ENKTL is a highly aggressive non-Hodgkin lymphoma closely related to EBV infection，and
advanced patients often suffer from hemophagocytic lymphohistiocytosis (HLH). ENKTL-HLH lacks
standard treatment and experiences a extremely poor prognosis. Anti-PD-1 antibody has shown
good anti-tumor activity in ENKTL and play a potential role in EBV-HLH. Epigenetic drugs have
been confirmed to exert synergistic anti-tumor activity with anti-PD-1 antibody. We next
further explore the efficacy and safety of Sintilimab sequential combination of epigenetic
drugs in ENKTL-HLH.